胜肽合成市场 - 2018-2028F 全球产业规模、份额、趋势、机会和预测，按产品、技术、按应用、最终用户、地区、竞争细分

2022 年，全球肽合成市场估值为42 亿美元，预计在预测期内将出现强劲增长，到2028 年复合年增长率为5.8%。肽是透过一种氨基酸的羧基与一种氨基酸的羧基偶联来合成的。另一个胺基酸分子的氨基。通常会采用保护措施来避免意外反应。化学胜肽合成通常从胜肽的羧基端开始，向氨基端进展，这与蛋白质生物合成的方向相反。胜肽作为高效和选择性的信号分子，与特定的细胞表面受体（例如离子通道或G蛋白偶联受体（GPCR））结合，引发细胞内反应。其卓越的药理学特征和内在特性使胜肽成为开发新疗法的理想起点。值得注意的是，胜肽由于其特异性而在人类中表现出卓越的安全性、耐受性和功效。与基于蛋白质的生物製药相比，胜肽疗法表现出较低的加工复杂性，导致生产成本更类似于小分子。

主要市场驱动因素

增加在製药业的使用

市场概况
预测期	2018-2028
2022 年市场规模	41907万美元
2028 年市场规模	6.0215亿美元
2023-2028 年复合年增长率	6.08%
成长最快的细分市场	製药和生物技术公司
最大的市场	北美洲

肽是高效且有针对性的药理成分，具有多种生物作用。它们广泛的化学空间、显着的生物活性和特异性，加上合成相对简单、易于使用和低毒性，使胜肽成为活性药物成分的有希望的候选者。肽可以被设计为专门针对体内的某些受体、酶或蛋白质，从而实现高度针对性和精确的治疗干预。这种有针对性的方法降低了脱靶效应的风险并提高了治疗效果。胜肽具有广泛的治疗应用，包括治疗癌症、代谢失调、心血管疾病、自体免疫疾病和传染病。

肽在糖尿病的应用

市场的显着成长可归因于消费者保健产业中胜肽的采用显着增加。胜肽在治疗各种生活方式障碍方面具有广泛的应用，包括癌症、糖尿病和肥胖症。这些代谢和生活方式疾病的盛行率不断上升，为胜肽疗法在肿瘤学和代谢疾病中的应用提供了机会。例如，根据国际糖尿病联盟发布的2021年统计数据，全球有5.37亿成年人（20-79岁）患有糖尿病，占糖尿病患者的十分之一。此外，同一消息来源报告称，5.41 亿成年人患有葡萄糖耐受性受损 (IGT)，使他们面临患 2 型糖尿病的高风险。已知多种胜肽疗法，例如胰高血糖素样胜肽-1酰胺，可以刺激餐后胰岛素分泌，并广泛用于胰臟治疗。因此，对肽类药物的需求预计将随着糖尿病患者数量的增加而增长，从而在整个预测期内推动市场发展。

专注于新的基于胜肽的治疗：

人们对胜肽作为潜在疗法及其在製药、生物技术和诊断等各个领域的多样化应用的兴趣日益浓厚，导致研究活动不断增加。研究人员正在探索新的基于胜肽的治疗方法并开发适用于多种医疗状况的胜肽药物，从而推动了对胜肽合成的需求。胜肽类新药的成功研发和批准引起了製药业的热情。随着更多基于胜肽的疗法获得监管部门的批准，胜肽合成设备和服务的市场不断扩大，以满足这些创新药物的需求。

由于研究活动的增加、新产品的批准以及研发资金的增加，胜肽合成市场经历了显着的成长。先进的胜肽合成仪在这一增长中发挥了至关重要的作用。值得注意的是，2021 年 4 月，ISSAR Pharma 宣布获得基于胜肽的新化学实体 (NCE) 的许可，以及预研究新药 (IND) 申请和一项美国专利。肽药物的这些显着发展预计将推动市场需求。

扩展诊断和成像应用

基于胜肽的生物感测器专门设计用于检测生物样品中的生物分子或分析物。这些生物感测器在早期疾病检测、监测治疗反应和测量各种生化参数方面具有巨大潜力。透过掺入对目标分子具有高亲和力和选择性的胜肽序列，可以确保准确和灵敏的检测。

胜肽用于开发可与体内疾病相关标靶结合的显影剂。这些显影剂在分子影像技术中发挥至关重要的作用，例如正子断层扫描（PET）、单光子发射电脑断层扫描（SPECT）和磁振造影（MRI）。基于胜肽的影像剂提供疾病部位的非侵入性和有针对性的可视化，极大地有助于诊断和治疗计划。基于胜肽的生物感测器、成像剂和生物标记的进步在诊断应用中至关重要。对非侵入性和标靶诊断工具（包括基于胜肽的显影剂和生物感测器）的需求不断增长，正在推动市场成长。

主要市场挑战

纯化和品质控制

在胜肽合成过程中，可能会形成杂质和副反应，影响最终产物的纯度。要实现高纯度需要仔细优化合成条件以尽量减少杂质的形成。然而，维持高纯度可能需要大量资源，需要大量的试剂、溶剂和专用设备。纯化成本占总生产费用。从小规模扩大到大规模胜肽合成对保持一致的纯度水平提出了挑战。反应动力学和传质等因素在较大范围内可能会有所不同，需要额外的製程优化。胜肽在研究和治疗中的成功应用依赖于获得高纯度的胜肽。高效液相层析 (HPLC) 等纯化方法可能非常耗时，并且需要对每个胜肽序列进行最佳化。确保合成胜肽的准确、一致和安全需要品质控制措施。满足高品质标准并实施高效的纯化製程对胜肽合成市场提出了挑战。

监管问题

胜肽在治疗心血管和神经系统疾病、肾衰竭和罕见疾病方面受到高度追捧。目前，市场上提供超过 100 种经 FDA 批准的胜肽类药物。处于临床试验或临床前研究阶段的多肽药物数量超过700个，拓展潜力大。这些以胜肽为基础的药物分为小分子和大分子生物製剂。然而，它们介于小分子和大蛋白质之间的独特地位带来了监管挑战。虽然大多数这些药物都是化学合成的，但它们的作用机制差异很大。

制定全面的监管规则来充分满足具有不同作用模式的多种分子实体的安全和品质要求是一项复杂的任务。此类药物缺乏既定的监管标准，使问题更加复杂。此外，美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 在胜肽类药物的监管许可方面存在差异。 FDA 将胜肽类药物归类为小分子药物，由 FDA 药物评估和研究中心 (CDER) 负责，而 EMA 则倾向于采用集中方式而不是相互认可程序。

缺乏统一的监管指南阻碍了治疗性胜肽获得许可，限制了其应用领域。因此，它成为全球肽合成行业成长的重大障碍。

主要市场趋势

扩大罕见疾病治疗的机会

可以对胜肽进行策略性设计，以针对与罕见疾病相关的特定分子途径或基因突变。这种以精确为导向的方法可以实现更有效和量身定制的治疗干预措施。可以客製化胜肽来解决特定的罕见突变或基因变异，从而允许透过个人化医疗方法针对个别患者进行个人化治疗。基于胜肽的疗法通常提供非侵入性递送选择，这使得它们成为对侵入性手术耐受性有限的罕见疾病患者的有吸引力的选择。监管机构为治疗罕见疾病的药物提供激励措施和特殊指定，为公司在该领域进行研究和开发创造机会。

胜肽为治疗罕见遗传性疾病和孤儿疾病提供了有前景的解决方案。肽合成市场的成长为开发和製造针对这些病症的胜肽疗法提供了机会。公司可以专注于设计和合成专门针对与罕见疾病相关的分子标靶的胜肽，从而解决未满足的医疗需求。

胜肽在个人化医疗发展的应用

个体化治疗的概念旨在实现最佳反应并最大化安全裕度以加强患者护理，这引起了人们对个别化治疗的浓厚兴趣。蛋白质体分析为破解不同组织（无论是健康组织还是患病组织）的分子谱提供了一种有吸引力且有效的方法。个人化蛋白质体学或蛋白质体学分析的出现代表了理解疾病路径机制的重大进步。

在欧盟资助的 ElectroMed 计画框架内，研究人员提议开发一个用户友好的平台，以促进电化学引导的胜肽合成。这项创新平台将基于微流控多重系统，由软体控制，从而促进蛋白质体学在个人化医疗中更广泛的应用。

此外，利用奈米材料的无标记感测器将用于检测和量化配体-受体复合物。这项技术进步将能够自动注射配体合成所需的各种试剂，从而促进个人化治疗背景下的个人化和受控胜肽合成。

对个人化医疗的投资不断增加，很大程度上归因于癌症和心血管疾病（CVD）等疾病盛行率的上升，以及对副作用最小的治疗的需求不断增长。个人化医疗有潜力提高医疗质量，同时降低成本。因此，肽合成市场的参与者将从客製化医疗领域的这些进步中受益。

细分市场洞察

技术洞察

在整个预测期内，液相肽合成（LPPS）一直是全球市场的主导部分，而固相肽合成则表现出最高的成长率。液相和固相胜肽合成的自动化和进步的整合极大地降低了胜肽合成的成本。因此，预计这将推动肽合成的全球采用，从而导致预测期内全球范围内的收入增加。传统研究表明，固相胜肽合成是一种适合 GMP 生产和 API 製程开发的方法，因为它在合成较小体积的长胜肽序列（超过 10 个胺基酸）方面具有成本效益。然而，值得注意的是，与固相胜肽合成相关的纯化成本可能会增加任何生产规模的製造成本。另一方面，液相肽合成通常用于开发较短的胜肽序列和较大的体积。在某些情况下，混合方法用于大体积合成长序列。

最终使用者见解

2022年，製药和生技产业占收入份额的很大一部分。近年来，生物药物、生物分子和生物製药疗法的开发大幅成长。因此，生物技术和製药行业越来越关注胜肽和蛋白质作为药物发现的目标。儘管蛋白质和胜肽具有一些具有巨大治疗潜力的特征，但它们具有根本的差异。该公司现在提供客製化胜肽合成、受保护的胺基酸、胜肽库和试剂、活性药物成分 (API) 生产、良好生产规范 (GMP) 製造以及非天然胺基酸和衍生物。胜肽的特殊要求推动了广泛的研究，特别是在药物传输系统领域。许多生命科学公司正在采用创新策略进行基于胜肽的药物开发，以配製稳定、生物可利用且易于生产的组合物。给药系统（例如鼻腔、肠胃外、控释、经皮、脉衝和口服给药）正在取得显着进步，以增强胜肽给药的有效性。与其他小分子药物相比，胜肽通常表现出最小的毒性、高特异性和较少的毒理学挑战，从而促进了治疗药物的开发，否则会带来商业挑战。

区域见解：

北美将在 2022 年成为市场的主导地区。其对全球市场的重大贡献可归因于主要参与者的强大影响力。此外，该地区对胜肽合成技术的认识不断提高，以及对胜肽药物商业规模生产的日益关注，进一步巩固了其地位。

此外，预计亚太地区在预测期内将经历最高的成长率。这可以归因于该地区市场参与者的投资不断增加、对创新肽治疗的认识不断提高、政府和患者医疗保健支出的增加、跨国公司与当地参与者之间的分销合作以及低收入国家慢性病发病率的不断上升。和中等收入国家。

主要市场参与者

• 多胜肽组
• 默克公司
• 赛默飞世尔科技
• 烯胺有限公司
• 阿尔法化学
• CEM公司
• 金斯瑞
• AAPP技术公司
• 巴亨控股
• AnaSpec 公司

可用的客製化：

全球胜肽合成市场报告根据给定的市场资料，技术科学研究根据公司的具体需求提供客製化服务。该报告可以使用以下自订选项：

公司资讯

• 其他市场参与者（最多五个）的详细分析和概况分析。

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球胜肽合成市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依产品（设备、试剂及消耗品、其他）
  • 依技术分类（固相胜肽合成（SPPS）、溶液相合成（SPS）、液相胜肽合成（LPPS）
  • 按应用（治疗、诊断、研究）
  • 按最终用户（製药和生物技术公司、合约製造组织 (CMO)、学术和研究机构），
  • 按地区
  • 按公司划分 (2022)
• 市场地图

第 6 章：北美胜肽合成市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按产品分类
  • 依技术
  • 按应用
  • 按最终用户
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 7 章：欧洲胜肽合成市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按产品分类
  • 依技术
  • 按应用
  • 按最终用户
  • 按国家/地区
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太地区胜肽合成市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按产品分类
  • 依技术
  • 按应用
  • 按最终用户
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲胜肽合成市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按产品分类
  • 依技术
  • 按应用
  • 按最终用户
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第10章：中东和非洲多肽合成市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按产品分类
  • 依技术
  • 按应用
  • 按最终用户
  • 按国家/地区
• MEA：国家分析
  • 南非胜肽合成
  • 沙乌地阿拉伯胜肽合成
  • 阿联酋胜肽合成

第 11 章：市场动态

第 12 章：市场趋势与发展

第 13 章：全球胜肽合成市场：SWOT 分析

第14章：竞争格局

• 商业概览
• 产品供应
• 最近的发展
• 主要人员
• SWOT分析
  • PolyPeptide Group
  • Merck KGaA
  • Thermo Fisher Scientific
  • Enamine Ltd.
  • Alfa Chemistry
  • CEM Corporation
  • GenScript
  • AAPPTec
  • Bachem Holding
  • AnaSpec, Inc.

第 15 章：策略建议

第 16 章：关于我们与免责声明

The Global Peptide Synthesis Market was valued at USD 4.2 billion in 2022 and is projected to experience robust growth in the forecast period, with a CAGR of 5.8% through 2028. Peptides are synthesized through the coupling of the carboxyl group of one amino acid with the amino group of another amino acid molecule. Protective measures are commonly employed to avoid unintended reactions. Chemical peptide synthesis typically starts from the carboxyl end of the peptide, progressing towards the amino terminus, contrary to the direction of protein biosynthesis. Peptides act as highly effective and selective signaling molecules, binding to specific cell surface receptors such as ion channels or G protein-coupled receptors (GPCRs), triggering intracellular reactions. Their exceptional pharmacological profile and intrinsic characteristics make peptides an ideal starting point for the development of new therapies. Notably, peptides demonstrate exceptional safety, tolerability, and efficacy in humans due to their specificity. When compared to protein-based biopharmaceuticals, peptide therapeutics exhibit lower processing complexity, resulting in production costs more akin to small molecules.

Key Market Drivers

Increasing Use in Pharmaceutical Industry

Market Overview
Forecast Period	2018-2028
Market Size 2022	USD 419.07 Million
Market Size 2028	USD 602.15 Million
CAGR 2023-2028	6.08%
Fastest Growing Segment	Pharmaceutical and Biotechnology Companies
Largest Market	North America

Peptides are highly potent and targeted pharmacological ingredients, exhibiting a diverse range of biological actions. Their broad chemical space, remarkable biological activity, and specificity, coupled with their relative simplicity of synthesis, ready availability, and low toxicity, position peptides as promising candidates for active medicinal components. Peptides can be designed to specifically target certain receptors, enzymes, or proteins in the body, allowing for highly targeted and precise therapeutic interventions. This targeted approach reduces the risk of off-target effects and enhances therapeutic efficacy. Peptides have a wide range of therapeutic applications, including the treatment of cancer, metabolic disorders, cardiovascular diseases, autoimmune disorders, and infectious diseases.

Peptides make a significant contribution to the therapeutic landscape, particularly in the fields of oncology, diabetes, and obesity, generating billions of dollars in revenue. Moreover, the demand for peptides is steadily increasing for the treatment of renal failure, rare disorders, as well as cardiovascular and neurological conditions. Currently, there are over 100 peptide-based medications available, and with nearly 700 peptide medicines and therapeutic peptides in preclinical development, this number is projected to grow substantially.

Application of Peptides in Diabetes

The significant market growth can be attributed to the notable increase in the adoption of peptides in the consumer healthcare industries. Peptides have a diverse range of applications in treating various lifestyle disorders, including cancers, diabetes, and obesity. The rising prevalence of these metabolic and lifestyle disorders has opened up opportunities for the utilization of peptide therapeutics in oncology and metabolic disorders. For instance, according to the 2021 statistics published by the International Diabetes Federation, there were 537 million adults (20-79 years) living with diabetes worldwide, accounting for 1 in 10 individuals affected by diabetes. Additionally, the same source reported that 541 million adults had Impaired Glucose Tolerance (IGT), placing them at high risk of developing type 2 diabetes. Several peptide therapies, such as Glucagon-like peptide-1amide, are known to stimulate insulin secretion postprandially and are widely used in pancreatic therapy. As a result, the demand for peptide drugs is expected to rise in parallel with the increasing number of diabetic patients, thereby driving the market throughout the forecast period.

Focus on New Peptide-Based Treatments:

The growing interest in peptides as potential therapeutics and their diverse applications in various fields, such as pharmaceuticals, biotechnology, and diagnostics, has led to increased research activities. Researchers are exploring new peptide-based treatments and developing peptide drugs for a wide range of medical conditions, driving the demand for peptide synthesis. The successful development and approval of new peptide-based drugs have generated enthusiasm in the pharmaceutical industry. As more peptide-based therapies gain regulatory approval, the market for peptide synthesis equipment and services expands to meet the demand for these innovative drugs.

The peptide synthesis market has experienced significant growth, attributed to increased research activities, novel product approvals, and the rise in funding for research and development. Advanced peptide synthesizers have played a crucial role in this growth. Notably, in April 2021, ISSAR Pharma announced the licensing of their peptide-based New Chemical Entities (NCEs), along with pre-investigational new drug (IND) filing and a United States patent. These remarkable developments in peptide drugs are anticipated to drive market demand.

Expanding Applications in Diagnostics and Imaging

Peptide-based biosensors are specifically designed to detect biomolecules or analytes in biological samples. These biosensors have significant potential in early disease detection, monitoring treatment responses, and measuring various biochemical parameters. By incorporating peptide sequences with high affinity and selectivity for target molecules, accurate and sensitive detection can be ensured.

Peptides are utilized in the development of imaging agents that can bind to disease-related targets in the body. These imaging agents play a crucial role in molecular imaging techniques such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI). Offering non-invasive and targeted visualization of disease sites, peptide-based imaging agents greatly aid in diagnosis and treatment planning. The advancement of peptide-based biosensors, imaging agents, and biomarkers is pivotal in diagnostic applications. The growing demand for non-invasive and targeted diagnostic tools, including peptide-based imaging agents and biosensors, is driving market growth.

Key Market Challenges

Purification and Quality Control

During peptide synthesis, the formation of impurities and side reactions may occur, impacting the purity of the final product. Achieving high purity necessitates careful optimization of synthesis conditions to minimize impurity formation. However, maintaining high purity can be resource-intensive, requiring substantial amounts of reagents, solvents, and specialized equipment. The cost of purification contributes to overall production expenses. Scaling up from small-scale to large-scale peptide synthesis poses challenges in maintaining consistent purity levels. Factors such as reaction kinetics and mass transfer can differ at larger scales, requiring additional process optimization. The successful application of peptides in research and therapeutics relies on obtaining high-purity peptides. Purification methods like high-performance liquid chromatography (HPLC) can be time-consuming and require optimization for each peptide sequence. Ensuring accurate, consistent, and safe synthesized peptides calls for quality control measures. Meeting high-quality standards and implementing efficient purification processes presents a challenge for the peptide synthesis market.

Regulatory Issues

Peptides are highly sought after for the treatment of cardiovascular and neurological disorders, renal failure, and rare diseases. Currently, the market offers over 100 FDA-approved peptide-based medications. The number of peptide medicines in clinical trials or preclinical research surpasses 700, indicating significant potential for expansion. These peptide-based medications are classified as both small-molecule and large-molecule biologics. Yet, their unique position between small molecules and large proteins poses regulatory challenges. While most of these medications are chemically synthesized, their mechanisms of action vary widely.

Developing comprehensive regulatory rules that sufficiently address the safety and quality requirements for such a diverse range of molecular entities with distinct modes of action is a complex task. The absence of established regulatory criteria for this class of medications further complicates matters. Moreover, there is a disparity between the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) regarding the regulatory clearance of peptide-based medications. The FDA classifies peptide medications as small-molecule pharmaceuticals under the authority of the FDA's Center for Drug Evaluation and Research (CDER), while the EMA favors a centralized approach over the mutual recognition procedure.

This lack of uniform regulatory guidelines hampers the acquisition of permits for therapeutic peptides, limiting their application areas. Consequently, it serves as a significant barrier to the growth of the global peptide synthesis industry.

Key Market Trends

Expanding Opportunities in Therapeutics for Rare Diseases

Peptides can be strategically designed to target specific molecular pathways or genetic mutations associated with rare diseases. This precision-oriented approach enables more effective and tailored therapeutic interventions. Peptides can be customized to address specific rare mutations or genetic variants, allowing treatments to be personalized to individual patients through personalized medicine approaches. Peptide-based therapies often offer non-invasive delivery options, making them an attractive choice for patients with rare diseases who may have limited tolerance for invasive procedures. Regulatory agencies provide incentives and special designations for drugs developed to treat rare diseases, creating opportunities for companies to pursue research and development in this field.

Peptides offer promising solutions for the treatment of rare genetic disorders and orphan diseases. The growth of the peptide synthesis market presents an opportunity to develop and manufacture peptide-based therapeutics targeting these conditions. Companies can focus on designing and synthesizing peptides that specifically target molecular targets associated with rare diseases, thereby addressing unmet medical needs.

Utilization of Peptides in the Advancement of Personalized Medicine

The concept of individualized therapy aimed at achieving the best response and maximizing safety margins to enhance patient care has generated significant interest in personalized treatment. Proteomic analysis presents an appealing and effective approach for deciphering the molecular profiles of distinct tissues, whether healthy or diseased. The emergence of personalized proteomics or proteomic profiling represents a significant stride forward in understanding disease path mechanisms.

Within the framework of the EU-funded ElectroMed project, researchers have proposed the development of a user-friendly platform to facilitate electrochemically guided peptide synthesis. This innovative platform will be based on a microfluidic multiplexing system, controlled by software, thus promoting the broader application of proteomics in personalized medicine.

Additionally, label-free sensors utilizing nanomaterials will be employed to detect and quantify ligand-receptor complexes. This technological advancement will enable the automated injection of various reagents required for ligand synthesis, thereby facilitating personalized and controlled peptide synthesis in the context of personalized treatment.

The increasing investments in personalized medicine can be largely attributed to the rising prevalence of diseases such as cancer and cardiovascular disease (CVD), along with the growing demand for treatments with minimal adverse effects. Personalized medicine has the potential to enhance healthcare quality while simultaneously reducing costs. Consequently, players in the peptide synthesis market stand to benefit from these advancements in the field of customized medicine.

Segmental Insights

Technology Insights

Liquid-Phase Peptide Synthesis (LPPS) has been the dominant segment in the global market throughout the forecast period, while solid-phase peptide synthesis has exhibited the highest growth rate. The integration of automation and advancements in both liquid and solid-phase peptide synthesis has significantly contributed to cost reduction in peptide synthesis. As a result, it is anticipated that this will drive the global adoption of peptide synthesis, leading to increased revenue on a global scale during the forecast period. Conventional studies suggest that solid-phase peptide synthesis is a suitable approach for GMP manufacturing and API process development due to its cost-effectiveness in synthesizing long peptide sequences (more than 10 amino acids) with smaller volumes. However, it is important to note that purification costs associated with solid-phase peptide synthesis can potentially increase manufacturing costs at any scale of production. On the other hand, liquid-phase peptide synthesis is commonly employed for developing shorter peptide sequences and larger volumes. In certain cases, hybrid approaches are utilized for synthesizing long sequences at large volumes.

End User Insights

The pharmaceutical and biotechnology sector accounted for a significant portion of the revenue share in 2022. In recent years, there has been a substantial surge in the development of biologic drugs, biomolecules, and biopharmaceutical therapeutics. Consequently, the biotech and pharmaceutical industries are increasingly focusing on peptides and proteins as targets for drug discovery. Although proteins and peptides share several characteristics with substantial therapeutic potential, they possess fundamental distinctions. Companies are now providing tailored peptide synthesis, protected amino acids, peptide libraries and reagents, Active Pharmaceutical Ingredient (API) production, Good Manufacturing Practice (GMP) manufacturing, as well as unnatural amino acids and derivatives. The specialized requirements of peptides drive extensive research, particularly in the realm of drug delivery systems. Numerous life sciences companies are adopting innovative strategies for peptide-based drug development to formulate stable, bioavailable, and manufacturing-friendly compositions. Notable advancements in administration systems, such as nasal, parenteral, controlled-release, transdermal, pulsatile, and oral delivery, are being made to enhance the effectiveness of peptide administration. Peptides often exhibit minimal toxicity, high specificity, and fewer toxicological challenges compared to other small molecule drugs, thereby facilitating the development of therapeutics that would otherwise pose commercial challenges.

Regional Insights:

North America emerged as the dominant region in the market in 2022. Its significant contribution to the global market can be attributed to the strong presence of major players. Moreover, the region's heightened awareness regarding peptide synthesis technologies and increasing focus on commercial-scale production of peptide drugs have further reinforced its position.

Also, the Asia Pacific region is projected to experience the highest growth rate during the forecast period. This can be attributed to the growing investments by market players in the region, rising awareness about innovative peptide treatments, increased healthcare spending by governments and patients, collaborations between multinational companies and local players for distribution, and the escalating incidence of chronic diseases in low- and middle-income countries.

Key Market Players

• PolyPeptide Group
• Merck KGaA
• Thermo Fisher Scientific
• Enamine Ltd.
• Alfa Chemistry
• CEM Corporation
• GenScript
• AAPPTec
• Bachem Holding
• AnaSpec, Inc.

Report Scope:

In this report, the Global Peptide Synthesis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptide Synthesis Market, By Product:

• Equipment
• Reagents and Consumables
• Others

Peptide Synthesis Market, By Technology:

• Solid-Phase Peptide Synthesis (SPPS)
• Solution-Phase Synthesis (SPS)
• Liquid-Phase Peptide Synthesis (LPPS)

Peptide Synthesis Market, By Application:

• Therapeutics
• Diagnosis
• Research

Peptide Synthesis Market, By End User:

• Pharmaceutical and Biotechnology Companies
• Contract Manufacturing Organization (CMO)
• Academic and Research Institutes

Peptide Synthesis Market, By Region:

• North America
  • United States
  • Canada
  • Mexico

• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea

• South America
  • Brazil
  • Argentina
  • Colombia

• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Peptide Synthesis Market.

Available Customizations:

Global Peptide Synthesis market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Peptide Synthesis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Equipment, Reagents and Consumables, Others)
  • 5.2.2. By Technology (Solid-Phase Peptide Synthesis (SPPS), Solution-Phase Synthesis (SPS), Liquid-Phase Peptide Synthesis (LPPS)
  • 5.2.3. By Application (Therapeutics, Diagnosis, Research)
  • 5.2.4. By End-User (Pharmaceutical and Biotechnology Companies, Contract Manufacturing Organization (CMO), Academic and Research Institutes),
  • 5.2.5. By Region
  • 5.2.6. By Company (2022)
• 5.3. Market Map

6. North America Peptide Synthesis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Peptide Synthesis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Peptide Synthesis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Peptide Synthesis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Peptide Synthesis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Peptide Synthesis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Peptide Synthesis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Peptide Synthesis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. France Peptide Synthesis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Peptide Synthesis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia-Pacific Peptide Synthesis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Peptide Synthesis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Peptide Synthesis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Peptide Synthesis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Peptide Synthesis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Peptide Synthesis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. South America Peptide Synthesis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Peptide Synthesis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Peptide Synthesis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Peptide Synthesis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. Middle East and Africa Peptide Synthesis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Peptide Synthesis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Peptide Synthesis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Peptide Synthesis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

12. Market Trends & Developments

13. Global Peptide Synthesis Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Product Offerings
• 14.3. Recent Developments
• 14.4. Key Personnel
• 14.5. SWOT Analysis
  • 14.5.1. PolyPeptide Group
  • 14.5.2. Merck KGaA
  • 14.5.3. Thermo Fisher Scientific
  • 14.5.4. Enamine Ltd.
  • 14.5.5. Alfa Chemistry
  • 14.5.6. CEM Corporation
  • 14.5.7. GenScript
  • 14.5.8. AAPPTec
  • 14.5.9. Bachem Holding
  • 14.5.10. AnaSpec, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer